IRIS PubliCatt

Patrono, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.428
EU - Europa 2.271
AS - Asia 743
SA - Sud America 38
OC - Oceania 17
AF - Africa 16
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.515
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.416
DE - Germania 537
CN - Cina 529
SE - Svezia 485
IT - Italia 343
UA - Ucraina 321
IE - Irlanda 188
FR - Francia 110
GB - Regno Unito 107
FI - Finlandia 71
IN - India 50
SG - Singapore 26
TR - Turchia 26
RU - Federazione Russa 19
IR - Iran 16
BE - Belgio 14
KR - Corea 14
CH - Svizzera 13
ES - Italia 13
BR - Brasile 12
PH - Filippine 12
HK - Hong Kong 11
CL - Cile 10
NL - Olanda 10
AU - Australia 9
CA - Canada 9
TH - Thailandia 9
CI - Costa d'Avorio 8
NZ - Nuova Zelanda 8
PK - Pakistan 8
PL - Polonia 7
VN - Vietnam 7
AT - Austria 6
ID - Indonesia 6
AR - Argentina 5
CZ - Repubblica Ceca 5
JP - Giappone 5
PE - Perù 5
RO - Romania 5
IQ - Iraq 4
DZ - Algeria 3
IL - Israele 3
MK - Macedonia 3
NO - Norvegia 3
VE - Venezuela 3
A1 - Anonimo 2
BH - Bahrain 2
CO - Colombia 2
EG - Egitto 2
GE - Georgia 2
KW - Kuwait 2
KZ - Kazakistan 2
LI - Liechtenstein 2
MD - Moldavia 2
MY - Malesia 2
NP - Nepal 2
PT - Portogallo 2
BD - Bangladesh 1
BG - Bulgaria 1
CM - Camerun 1
CR - Costa Rica 1
EC - Ecuador 1
GR - Grecia 1
KE - Kenya 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
MX - Messico 1
SA - Arabia Saudita 1
SD - Sudan 1
SI - Slovenia 1
SV - El Salvador 1
TJ - Tagikistan 1
TW - Taiwan 1
Totale 5.515
Salva come PNG Salva come JPEG
Città #
Chandler 408
Ashburn 227
Jacksonville 184
Dublin 174
San Mateo 156
Nanjing 133
Hangzhou 102
Wilmington 94
Beijing 90
Cattolica 87
Woodbridge 81
Ann Arbor 70
Boston 68
Lawrence 63
Menlo Park 50
Houston 48
Rome 46
Redwood City 45
Nanchang 41
Dearborn 39
Milan 38
Fairfield 36
Princeton 35
Seattle 29
Bremen 26
Mountain View 26
Redmond 26
Shenyang 24
New York 23
Hebei 22
Boardman 21
Kunming 21
Izmir 20
Lancaster 20
Bareggio 17
Chicago 17
Tianjin 16
Brussels 14
University Park 12
Jiaxing 11
Leawood 11
Norwalk 11
Nürnberg 11
Augusta 10
Hounslow 10
Singapore 10
Guangzhou 9
Abidjan 8
Detroit 8
London 8
Philadelphia 8
Pune 8
Shanghai 8
Washington 8
Edinburgh 7
Lanzhou 7
Los Angeles 7
Quezon City 7
Changsha 6
Hong Kong 6
Andover 5
Busto Arsizio 5
Catania 5
Changchun 5
Jakarta 5
Marseille 5
Ankara 4
Bangkok 4
Chieti 4
Florence 4
Garanhuns 4
Hefei 4
Indiana 4
Jinan 4
Karlsruhe 4
Kish 4
Latham 4
Lima 4
Moscow 4
Münster 4
Salò 4
Santiago 4
Uster 4
Vienna 4
Auckland 3
Avon 3
Cambridge 3
Coleraine 3
Falls Church 3
Groningen 3
Henderson 3
Islamabad 3
Kouba 3
Madrid 3
Melipilla 3
Monmouth Junction 3
Munich 3
North York 3
Pederobba 3
Prilep 3
Totale 2.978
Salva come PNG Salva come JPEG
Nome #
Antiplatelet agents for the treatment and prevention of atherothrombosis 160
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) 140
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes 122
Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors 113
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 108
In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus 106
Aspirin Continues to Attract Research and Debate, 115 Years After Its Synthesis 103
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 100
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes 95
Nutraceuticals in diabetes and metabolic syndrome. 94
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) 88
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 88
Increased thromboxane biosynthesis in essential thrombocythemia. 83
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. 82
Platelet activation and atherothrombosis 79
Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. 79
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis 78
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 78
Drug insight: aspirin resistance- fact or fashion 77
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 75
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. 75
Type 2 Diabetes, Obesity, and Aspirin Responsiveness* 73
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells 73
Aspirin: promise and resistance in the new millennium. 72
Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective 71
Antiplatelet therapy:aspirin for asymptomatic atherosclerosis? 70
In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia 70
The future of antiplatelet therapy in cardiovascular disease 69
Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C →T polymorphism 69
Non-steroidal anti-inflammatory drugs 67
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 67
Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment 66
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 66
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials 61
Platelet progenitors: the hidden drug target 61
Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) 60
Aspirin 60
Low-Dose Aspirin, Coxibs, and other NSAIDS: A clinical Mosaic Emerges. 59
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy 59
Eicosanoid biosynthesis and metabolism in myeloproliferative disorders 57
Determinants of platelet activation in Alzheimer's disease. 57
Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials 57
Low-dose aspirin for the prevention of atherothrombosis 57
Aspirin 56
Fourth universal definition of myocardial infarction (2018) 56
Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. 55
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 54
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 54
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective 54
Determinants of the interindividual variability in response to antiplatelet drugs. 53
Prostanoids, aspirin and related compounds 52
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 52
The role of aspirin in cancer prevention 51
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety 50
Nonsteroidal antiinflammatory drugs: past, present and future 49
Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. 48
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 48
Interindividual Variability in response to aspirin and P2Y12 blockers in patients at high cardiovascular risk-the state of the evidence 47
Cigarette smoking knowledge and perceptions among students in four italian medical schools 46
Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. 45
Cyclooxygenase inhibitors: From pharmacology to clinical read-outs 45
The coxibs, selective inhibitors of cyclooxygenase-2 45
Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. 44
Aspirin and Other COX-1 Inhibitors 44
The Key Contribution Of Platelet And Vascular Arachidonic Acid Metabolism To The Pathophysiology Of Atherothrombosis 44
Diabetes: Does aspirin increase the risk of major bleeds? 43
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 42
Aspirin, 110 years later 40
Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? 40
The P2Y12 receptor: no active metabolite, no party 39
Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development 39
Antiplatelet Therapy 39
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets 38
The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin 38
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis 38
Effect of low-dose and standard-dose aspirin on PGE2 biosynthesis among individuals with colorectal adenomas: A randomized clinical trial 37
Mechanisms, consequences, and prevention of coronary graft failure 37
In Silico Modeling of the Antiplatelet Pharmacodynamics of Low-dose Aspirin in Health and Disease 35
Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development 34
Selective COX-2 inhibitors: where do we go from here? 34
Nonsteroidal anti-inflammatory drugs and the heart 33
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance" 32
Knowledge about health effects of cigarette smoking and quitting among Italian university students: the importance of teaching nicotine dependence and treatment in the medical curriculum 32
Measurement of Thromboxane Biosynthesis in Health and Disease 31
Aspirin at 120: Retiring, recombining, or repurposing? 31
Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer 29
Role of Clinical Pharmacology in the Development of Antiplatelet Drugs 28
Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now 28
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 26
Aspirin and Cancer 24
Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus. Role of interleukin-6 and disease duration. 23
Precision antiplatelet therapy 18
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 18
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials 18
Less Thromboxane, Longer Life 17
Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation 15
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs 15
Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Implications for Aspirin "Resistance" 15
Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues 14
Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera 14
Totale 5.570
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.912
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.912
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201956 0 0 0 0 0 0 0 0 0 0 38 18
2019/2020703 190 25 33 22 59 44 37 33 44 47 86 83
2020/2021770 71 83 9 75 104 74 73 23 87 15 124 32
2021/2022787 73 74 12 51 62 21 25 128 38 25 112 166
2022/20231.367 209 189 123 164 146 160 37 93 145 23 51 27
2023/2024645 23 235 35 81 36 53 57 30 14 34 47 0
Totale 5.613